Who
Sukumar Nagendran
President and Head of R&D
Company insider
Files Form 4 as: President and Head of R&D, Taysha Gene Therapies; Director, Solid Biosciences; Sr. VP & Chief Medical Officer, AveXis.
In numbers
- Trades disclosed
- 142
- Buys
- 2
- Sells
- 21
- Bought
- $84K
- Sold
- $11.8M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 20 Jun 2016
- Last trade
- 10 Jul 2026
- Last filed
- 10 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jul 2026filed 10 Jul 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $1.2M200,000 at $6.24 | filing |
| 10 Jul 2026filed 10 Jul 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $1.2M200,000 at $6.24 | filing |
| 10 Jun 2026filed 11 Jun 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 10 Jun 2026filed 11 Jun 2026 | SLDB Solid Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —77,500 at $0.00 | filing |
| 10 Apr 2026filed 13 Apr 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code M | $33K19,021 at $1.71 | filing |
| 10 Apr 2026filed 13 Apr 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $892K200,000 at $4.46 | filing |
| 10 Apr 2026filed 13 Apr 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,021 at $0.00 | filing |
| 10 Apr 2026filed 13 Apr 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,021 at $0.00 | filing |
| 10 Apr 2026filed 13 Apr 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code M | $33K19,021 at $1.71 | filing |
| 10 Apr 2026filed 13 Apr 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $892K200,000 at $4.46 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $124K26,918 at $4.61 | filing |
| 26 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $124K26,918 at $4.61 | filing |
| 23 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $423K89,132 at $4.75 | filing |
| 23 Jan 2026filed 27 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $423K89,132 at $4.75 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code M | $78K111,324 at $0.6989 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Code M | $152K88,676 at $1.71 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene TherapiesBiotechnology | SEC FORM 4 Sold | $942K200,000 at $4.71 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code M | —111,324 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code M | —88,676 at $0.00 | filing |
| 12 Jan 2026filed 14 Jan 2026 | TSHA Taysha Gene Therapiesoption or derivative · Biotechnology | SEC FORM 4 Code A | —274,000 at $0.00 | filing |
News
Head-To-Head Survey: Taysha Gene Therapies (NASDAQ:TSHA) vs. MediWound (NASDAQ:MDWD)TSHA · dailypolitical.com · 12 Oct 2026
0 headlines in the last 90 days name Sukumar Nagendran; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.